BRAF/MEK Combo Active across Tumor Types.
The BRAF/MEK inhibitor combination dabrafenib/trametinib is effective in a wide array of rare BRAF-mutant cancers, according to findings from the NCI-MATCH trial presented at the 2019 American Society of Clinical Oncology Annual Meeting in Chicago, IL. In the trial, the combination elicited partial responses in 33% of patients and led to stable disease in another 39% of patients with rare BRAF V600E-mutant malignancies.